Pablo Corral: The ANGPTL Axis in Dyslipidemia and Cardiovascular Risk
Pablo Corral, Pharmacology Professor at FASTA University, Past President of Argentine Lipid Society, shared a post on LinkedIn about a recent article by Isabela C. Bitencourt et al., published in Current Atherosclerosis Reports, adding:
“The Angiopoietin-like Protein (ANGPTL) Axis in Dyslipidemia: Mechanisms, Cardiovascular Risk, and Emerging Therapies
The ANGPTL axis is rapidly becoming one of the most exciting frontiers in lipid therapeutics.
- ANGPTL3 inhibition lowers TG, remnants, LDL-C and apoB — importantly, through mechanisms largely independent of the LDL receptor.
- HoFH is already proof of concept: evinacumab reduced LDL-C by approximately 49%, irrespective of LDLR genotype.
- RNA therapeutics such as zodasiran and solbinsiran are expanding the field, providing sustained ANGPTL3 suppression and broad reductions in atherogenic lipoproteins.
- ANGPTL3/8 and ANGPTL4 are emerging as additional targets, particularly for TG- and remnant-rich dyslipidemia.
- And perhaps the most disruptive concept: one-time in vivo CRISPR-Cas9 editing of ANGPTL3, with early human data showing up to 80% ANGPTL3 suppression and sustained reductions in TG and LDL-C.
The key unanswered question: will these impressive lipid changes translate into fewer cardiovascular events?
The future of lipid lowering may not simply be about targeting another lipid, but about rewiring the pathways that control atherogenic lipoprotein metabolism.”
Title: The Angiopoietin-like Protein (ANGPTL) Axis in Dyslipidemia: Mechanisms, Cardiovascular Risk, and Emerging Therapies
Authors: Isabela C. Bitencourt, André Zimerman, Nicholas A. Marston

Other featuring Pablo Corral on Hemostasis Today.
-
Nov 20, 2026, 17:27Adam Bryant: Great Science, Valuable Connections and a Wonderful Haematology Community at Blood 2026
-
Nov 20, 2026, 17:25Gurpreet Kaurr: Scientific Discussions, New Perspectives and Inspiration at HAEMATOCON 2026
-
Nov 20, 2026, 17:24Bispecific FVIIIa-Mimetic Antibodies in Haemophilia A – CRH French Reference Center for Hemophilia Lyon
-
Nov 20, 2026, 17:23Khalid Rehman: Psychosocial Burden Among Caregivers of Patients with Beta-Thalassemia Major in Pakistan
-
Nov 20, 2026, 17:20Dhinesh Selvaraju: Caplacizumab Becomes the First FDA-Approved Treatment for Pediatric aTTP
-
Nov 20, 2026, 17:19Paris Margaritis: Presenting Preclinical Data on GENV-HEM at the WFH Workshop
-
Nov 20, 2026, 17:18WFH Opens Public Comment on Draft Guidelines for Hemostatic Agents and Prophylaxis
-
Nov 20, 2026, 17:18Ketan Asawale: Consensus on the Management of Cancer-Associated Thrombosis in India
-
Nov 20, 2026, 17:16Ajay Samkaria: The Evolution of Hemostasis Diagnostics with the ACL TOP 70 Series